Usage: CAYSTON® is indicated for improving respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. It is not established for use in patients under 7, those with FEV1 <25% or >75%, or those colonized with Burkholderia cepacia. It should only be used in confirmed Pseudomonas infections.
Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.
Usage: DESCOVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents. It is also approved for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg), excluding those at risk from receptive vaginal sex.
Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.
Usage: ODEFSEY is indicated for the treatment of HIV-1 infection in patients weighing at least 25 kg, either as initial therapy for those with no prior treatment history and HIV-1 RNA ≤ 100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients.
Usage: STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.